Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report

Overview of attention for article published in Frontiers in oncology, July 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 17 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 7,628 followers.

RT @FrontOncology: New research: Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abun…

06 Sep 2020

Reply Repost Favourite

New research: Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report: EML4-ALK fusions are targetable oncogenic drivers in a subset of… https://t.co/s

06 Sep 2020

Reply Repost Favourite

PubMed_ Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report. https://t.co/715qzF1lCR

28 Aug 2020

Reply Repost Favourite

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report. https://t.co/Ej9Z1Nnov1 https://t.co/pjYjrARIl4

28 Aug 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.